157 related articles for article (PubMed ID: 37715782)
1. NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C; Kilian M; Chih YC; Kourtesakis A; Hoffmann DC; Boschert T; Koopmann P; Sanghvi K; De Roia A; Jung S; Jähne K; Day B; Shultz LD; Ratliff M; Harbottle R; Green EW; Will R; Wick W; Platten M; Bunse L
Neuro Oncol; 2024 Feb; 26(2):266-278. PubMed ID: 37715782
[TBL] [Abstract][Full Text] [Related]
2. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
3. T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Kilian M; Friedrich M; Sanghvi K; Green E; Pusch S; Kawauchi D; Löwer M; Sonner JK; Krämer C; Zaman J; Jung S; Breckwoldt MO; Willimsky G; Eichmüller SB; von Deimling A; Wick W; Sahm F; Platten M; Bunse L
Clin Cancer Res; 2022 Jan; 28(2):378-389. PubMed ID: 34782365
[TBL] [Abstract][Full Text] [Related]
4. TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma.
Schaettler MO; Desai R; Wang AZ; Livingstone AJ; Kobayashi DK; Coxon AT; Bowman-Kirigin JA; Liu CJ; Li M; Bender DE; White MJ; Kranz DM; Johanns TM; Dunn GP
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808076
[TBL] [Abstract][Full Text] [Related]
5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
6. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study.
Safarzadeh Kozani P; Shokrgozar MA; Evazalipour M; Roudkenar MH
Int Immunopharmacol; 2022 Sep; 110():109055. PubMed ID: 35853277
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
9. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
[TBL] [Abstract][Full Text] [Related]
11. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
12. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
13. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
14. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Lustgarten J; Waks T; Eshhar Z
Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
[TBL] [Abstract][Full Text] [Related]
15. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
16. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
[TBL] [Abstract][Full Text] [Related]
18. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
19. The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.
Han X; Ye P; Luo L; Zheng L; Liu Y; Chen L; Wang S
Cell Mol Immunol; 2011 Jul; 8(4):333-40. PubMed ID: 21643003
[TBL] [Abstract][Full Text] [Related]
20. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
